Identifying and developing products that will improve the health and quality of life of patients remains a
primary focus of Forest Laboratories. Our current product pipeline includes therapies in all stages of
development and across a wide range of therapeutic areas, including cardiovascular disease, chronic obstructive
pulmonary disease (COPD), mental health conditions, Alzheimer’s disease, infectious disease, and pain management.
Below is a partial listing of our pipeline products.
Click here to see Aptalis pipeline products.
* Nebivolol is marketed in the U.S. as BYSTOLIC®
† Memantine ER is marketed in the U.S. as NAMENDA XR®
‡ Aclidinium is marketed in the U.S. as TUDORZA®
Except for the historical information contained herein, this site contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of
risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for
new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch
of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings. Forest assumes no obligation to
update forward-looking statements contained here to reflect new information or future events or developments.
With a unique partnership-focused business model and a strong track record
of commercial achievement, Forest has built a pharmaceutical business for
today's environment. The Company is fulfilling its objective of making a
meaningful difference in patients' lives through an expanded and diversified
product portfolio and the most robust pipeline in our history.
Forest employees are driven by a shared passion to help improve patients' lives
through medicine. Forest offers a variety of opportunities for experienced professionals,
sales professionals, graduate students, and others to build their careers in a
about joining our team.
Thank you for visiting www.FRX.com.
You are now being redirected to an external site.